EA
CYTK icon

Emerald Advisers’s Cytokinetics CYTK Stock Holding History

Emerald Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39M Buy
457,956
+259,145
+130% +$18.6M 0.92% 41
2026
Q1 		$13.1M Buy
+198,811
New +$12.6M 0.41% 90
2024
Q2 		– Sell
-91,561
Closed -$6.42M – 254
2024
Q1 		$6.42M Buy
+91,561
New +$7.08M 0.26% 111
2023
Q2 		– Sell
-237,617
Closed -$8.36M – 218
2023
Q1 		$8.36M Sell
237,617
-234,693
-50% -$9.57M 0.4% 93
2022
Q4 		$21.6M Buy
472,310
+131,700
+39% +$5.67M 1.05% 38
2022
Q3 		$16.5M Buy
340,610
+196,300
+136% +$9.45M 0.85% 50
2022
Q2 		$5.67M Buy
+144,310
New +$5.81M 0.29% 105

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers's CYTK Position: Q2 2026 in Review

Emerald Advisers increased its Cytokinetics (CYTK) stake by 130% in Q2 2026, buying an estimated $18.6M and bringing the position to 457,956 shares worth $39M. The position accounts for 0.92% of the portfolio, ranked #41.

Emerald Advisers first reported a position in CYTK in Q2 2022 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Emerald Advisers held 457,956 shares of Cytokinetics worth $39M as of Q2 2026.
  • Emerald Advisers bought 259,145 Cytokinetics shares in Q2 2026, an estimated $18.6M.
  • Cytokinetics made up 0.92% of Emerald Advisers's portfolio in Q2 2026, its #41 holding.
  • Emerald Advisers first reported a position in Cytokinetics in Q2 2022 and has held it in 7 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.